Luís Miguel Correia Teixeira

Luís Miguel Correia Teixeira

Auto-generated profile, based on publicly available information

Luís Miguel Correia Teixeira

LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências Universidade do Porto, Rua do Campo Alegre, s/n, 4169-007 Porto, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
PPPedro Paiva
Pedro Paiva
LTLuís Miguel Correia Teixeira
Luís Miguel Correia Teixeira
R. WeiR. Wei
R. Wei
WLWeidong Liu
Weidong Liu
GWGert Weber
Gert Weber
MRMaria Ramos
Maria Ramos
This work uncovers the detailed catalytic mechanism of UMG-SP2 urethanase, offering insights into improving PU degradation.

20 December 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
LRLaura Rotilio
Laura Rotilio
Thomas BayerThomas Bayer
Thomas Bayer
HMHannes Meinert
Hannes Meinert
LTLuis M. C. Teixeira
Luis M. C. Teixeira
MJMartin B. Johansen
Martin B. Johansen
JMJ. Preben Morth
J. Preben Morth

5 April 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
RSRafaela Sousa
Rafaela Sousa
CCCleópatra Caldeira
Cleópatra Caldeira
SPSoraya S. Pereira
Soraya S. Pereira
SSSaulo Silva
Saulo Silva
Pedro Alexandrino FernandesPedro Alexandrino Fernandes
Pedro Alexandrino Fernandes
ASAndreimar Soares
Andreimar Soares

12 May 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
LTLuís M. C. Teixeira
Luís M. C. Teixeira
JCJoão T. S. Coimbra
João T. S. Coimbra
MRMaria Ramos
Maria Ramos
Pedro Alexandrino FernandesPedro Alexandrino Fernandes
Pedro Alexandrino Fernandes
Despite the development of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, there is an urgent need for efficient drugs to treat infected patients. An attractive drug target is the human transmembrane protease serine 2 (TMPRSS2) because of its vital role in the viral infection mechanism of SARS-CoV-2 by activation of the virus spike protein (S protein). Having in mind that the information derived from quantum mechanics/molecular mechanics (QM/MM) studies could be an important tool in the design of transition-state (TS) analogue inhibitors, we resorted to adiabatic QM/MM calculations to determine the mechanism of the first step (acylation) of proteolytic cleavage of the S protein with atomistic details. Acylation occurred in two stages: (i) proton transfer from Ser441 to His296 concerted with the nucleophilic attack of Ser441 to the substrate's P1-Arg and (ii) proton transfer from His296 to the P1'-Ser residue concerted with the cleavage of the ArgP1-SerP1' peptide bond, with a Gibbs activation energy of 17.1 and 15.8 kcal mol-1, relative to the reactant. An oxyanion hole composed of two hydrogen bonds stabilized the rate-limiting TS by 8 kcal mol-1. An analysis of the TMPRSS2 interactions with the high-energy, short-lived tetrahedral intermediate highlighted the limitations of current clinical inhibitors and pointed out specific ways to develop higher-affinity TS analogue inhibitors. The results support the development of more efficient drugs against SARS-CoV-2 using a human target, free from resistance development.

9 August 2025 in ACS Catalysis
Verified
Journal Article
Closed access
LTLuís M. C. Teixeira
Luís M. C. Teixeira
PPPedro Paiva
Pedro Paiva
MJMartin B. Johansen
Martin B. Johansen
ASAndreas Sommerfeldt
Andreas Sommerfeldt
APAllan R. Petersen
Allan R. Petersen
MRMaria Ramos
Maria Ramos

20 December 2024 in Angewandte Chemie
Verified
Journal Article
Closed access
LRLaura Rotilio
Laura Rotilio
Thomas BayerThomas Bayer
Thomas Bayer
HMHannes Meinert
Hannes Meinert
LTLuis M. C. Teixeira
Luis M. C. Teixeira
MJMartin B. Johansen
Martin B. Johansen
JMJ. Preben Morth
J. Preben Morth